PA

Pathway Bioventures

VC
Cambridge, MAWebsite

Pathway Bioventures is a Pre-Seed, Seed venture capital firm based in Cambridge, MA investing in Healthcare, Other. The firm typically writes $250K–$3.0M checks and has 16 portfolio companies in our records.

How to approach: warm intro preferred
Stage

Pre-Seed, Seed

Check Size

$250K – $3.0M

Portfolio

16+ companies

Team

5 partners

Investor activity
Investments in last 12 months: 0

Investment Thesis

Dedicated to early-stage biotech with cutting-edge innovations in oncology and cell therapy solutions, focusing on niche applications.

How Pathway Bioventures invests

Pathway Bioventures is a vc firm based in Cambridge, MA. The firm invests at the Pre-Seed, Seed stages, with a focus on Healthcare, Other. It does not invest in Consumer, Media.

Pathway Bioventures typically writes checks of $250K–$3.0M per investment.

Pathway Bioventures has backed 16 companies in our records, including BioRegen Therapeutics, TumorTarget Biotech, AIRNA Therapeutics.

Meet the Team

DJ

Daniel Jacobs

Managing Partner

DJ

Daniel Jacobs, PhD, MPH

Founder & Managing Partner

cancer epidemiology
genomics
RNA therapeutics
precision therapeutics
early-stage life sciences
MM

Matt Martin, PhD, MBA

Partner

therapeutics
unmet medical needs
life sciences startups
investment strategy
JS

Jacob Segil, PhD

Venture Partner

medical devices
neural interfaces
prosthetic devices
translation into devices
EN

Emily Nguyen

Founding GP

Biotech
Cell Therapy
HealthTech

Industry Focus

Invests In

Healthcare
Other

Does Not Invest In

Consumer
Media

Portfolio Companies (16)

Other

BI

BioRegen Therapeutics

Cell & Gene Therapy
TU

TumorTarget Biotech

Oncology
AI

AIRNA Therapeutics

RNA Editing·Preclinical development

Pioneering the discovery and development of RNA editing therapeutics for patients with rare and common diseases.

AX

AXONIS Therapeutics

Small Molecule·Preclinical development

Advancing breakthroughs in neuroscience to develop first-in-class precision therapies for neurological disorders.

BI

BioGraph55

Bispecific Antibody·Preclinical development

Developing bispecific antibodies against a novel subset of immunosuppressive cells to treat resistant cancers.

IP

IpiNovyx Bio

Small molecule·Preclinical development

Develops next-generation, ultra-selective proteasome inhibitors for oncology and autoimmune disease applications.

MI

miRecule

Antibody-RNA Conjugate·Preclinical development

Developing RNA-based therapeutics for cancer and muscular dystrophy.

MO

Modifi Bio

Small molecule·Preclinical-stage

Creating a new class of oral medicines that selectively kill cancer cells via direct DNA modification.

NI

Nionyx Bio

Gene therapy·Preclinical development

Developing transformative gene therapies for patients with severe kidney diseases.

OC

Ochre Bio

sirna·Preclinical development

Developing novel RNA-based therapeutics for chronic liver diseases.

How to pitch Pathway Bioventures
  • Raising at Pre-Seed, Seed? You're squarely in their sweet spot.
  • Lead with your fit in Healthcare, Other — the sectors they actively back.
  • Size your ask to their typical $250K – $3.0M check.
  • warm intro preferred
  • Address your outreach to a specific partner, such as Daniel Jacobs, Managing Partner.
  • A warm introduction beats a cold email. Get matched and request an intro.

Featured In

Browse More Investors

Fundraising resources

Frequently Asked Questions

See if Pathway Bioventures is a match for your startup

Upload your pitch deck to see how well you match with Pathway Bioventures and 10,000+ other investors.

Is this your profile? Request a correction or removal